Now bring us the pain results- a strong statement showing clinical progress and reaffirming commercial goals and timetables combined with the potential to recoup missing funds plus interest and expenses should turn our ship around. POH will get massive coverage now and in the weeks ahead over Esragate and while we are in the spotlight a great opportunity to showcase its game on for Oxypatch
financial misappropriation ann is out, page-13
-
- There are more pages in this discussion • 139 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(33.3%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.2¢ | $11.50K | 4.335M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 63 | 101422109 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 20872825 | 7 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVE (ASX) Chart |